- Home
- PLRX vs ARCT Comparison
PLRX vs ARCT Comparison
Compare PLRX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- ARCT
- Stock Information
- Founded
- PLRX 2015
- ARCT 2013
- Country
- PLRX United States
- ARCT United States
- Employees
- PLRX N/A
- ARCT N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- ARCT Health Care
- Exchange
- PLRX Nasdaq
- ARCT Nasdaq
- Market Cap
- PLRX 77.3M
- ARCT 298.3M
- IPO Year
- PLRX 2020
- ARCT N/A
- Fundamental
- Price
- PLRX $1.44
- ARCT $13.36
- Analyst Decision
- PLRX Hold
- ARCT Strong Buy
- Analyst Count
- PLRX 10
- ARCT 8
- Target Price
- PLRX $9.79
- ARCT $52.83
- AVG Volume (30 Days)
- PLRX 1.6M
- ARCT 484.0K
- Earning Date
- PLRX 08-06-2025
- ARCT 08-04-2025
- Dividend Yield
- PLRX N/A
- ARCT N/A
- EPS Growth
- PLRX N/A
- ARCT N/A
- EPS
- PLRX N/A
- ARCT N/A
- Revenue
- PLRX N/A
- ARCT $143,680,000.00
- Revenue This Year
- PLRX N/A
- ARCT N/A
- Revenue Next Year
- PLRX N/A
- ARCT $34.79
- P/E Ratio
- PLRX N/A
- ARCT N/A
- Revenue Growth
- PLRX N/A
- ARCT 15.38
- 52 Week Low
- PLRX $1.10
- ARCT $8.04
- 52 Week High
- PLRX $16.10
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- PLRX 55.31
- ARCT 54.34
- Support Level
- PLRX $1.13
- ARCT $13.10
- Resistance Level
- PLRX $1.27
- ARCT $15.20
- Average True Range (ATR)
- PLRX 0.11
- ARCT 1.02
- MACD
- PLRX 0.03
- ARCT 0.07
- Stochastic Oscillator
- PLRX 93.33
- ARCT 55.21
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.